Wilmington Savings Fund Society FSB Purchases 3,999 Shares of Cencora, Inc. $COR

Wilmington Savings Fund Society FSB boosted its position in Cencora, Inc. (NYSE:COR) by 552.3% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 4,723 shares of the company’s stock after buying an additional 3,999 shares during the quarter. Wilmington Savings Fund Society FSB’s holdings in Cencora were worth $1,476,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently made changes to their positions in COR. Vanguard Group Inc. increased its holdings in Cencora by 5.3% in the 2nd quarter. Vanguard Group Inc. now owns 22,479,041 shares of the company’s stock worth $6,740,340,000 after acquiring an additional 1,125,661 shares during the last quarter. Geode Capital Management LLC boosted its position in Cencora by 6.3% during the second quarter. Geode Capital Management LLC now owns 4,787,609 shares of the company’s stock worth $1,429,772,000 after purchasing an additional 284,229 shares during the period. Norges Bank purchased a new position in shares of Cencora in the second quarter worth about $695,215,000. Viking Global Investors LP raised its position in shares of Cencora by 95.0% in the second quarter. Viking Global Investors LP now owns 2,081,732 shares of the company’s stock valued at $624,207,000 after purchasing an additional 1,013,913 shares during the period. Finally, Amundi lifted its stake in shares of Cencora by 17.0% during the 2nd quarter. Amundi now owns 1,720,278 shares of the company’s stock valued at $500,893,000 after buying an additional 249,742 shares in the last quarter. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Insider Transactions at Cencora

In related news, EVP Elizabeth S. Campbell sold 3,351 shares of the company’s stock in a transaction on Friday, December 19th. The shares were sold at an average price of $342.10, for a total value of $1,146,377.10. Following the completion of the transaction, the executive vice president directly owned 23,891 shares in the company, valued at approximately $8,173,111.10. The trade was a 12.30% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Silvana Battaglia sold 1,677 shares of the firm’s stock in a transaction dated Friday, December 19th. The shares were sold at an average price of $345.00, for a total value of $578,565.00. Following the sale, the executive vice president owned 18,796 shares in the company, valued at $6,484,620. The trade was a 8.19% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 20,317 shares of company stock valued at $7,009,260. Insiders own 10.80% of the company’s stock.

Cencora Price Performance

Shares of NYSE COR opened at $354.96 on Friday. The stock’s 50-day simple moving average is $349.64 and its two-hundred day simple moving average is $320.12. Cencora, Inc. has a twelve month low of $237.71 and a twelve month high of $377.54. The firm has a market capitalization of $68.86 billion, a P/E ratio of 44.65, a P/E/G ratio of 1.69 and a beta of 0.66. The company has a quick ratio of 0.55, a current ratio of 0.90 and a debt-to-equity ratio of 4.32.

Cencora (NYSE:COR) last issued its quarterly earnings data on Wednesday, November 5th. The company reported $3.84 EPS for the quarter, topping the consensus estimate of $3.79 by $0.05. The company had revenue of $83.73 billion during the quarter, compared to analyst estimates of $83.36 billion. Cencora had a return on equity of 227.15% and a net margin of 0.48%.Cencora’s revenue was up 5.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $3.34 earnings per share. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. As a group, equities analysts anticipate that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, December 1st. Stockholders of record on Friday, November 14th were given a dividend of $0.60 per share. This is an increase from Cencora’s previous quarterly dividend of $0.55. The ex-dividend date was Friday, November 14th. This represents a $2.40 annualized dividend and a dividend yield of 0.7%. Cencora’s dividend payout ratio is 30.19%.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on COR shares. Wells Fargo & Company lifted their price objective on shares of Cencora from $354.00 to $405.00 and gave the company an “overweight” rating in a research note on Tuesday, November 11th. TD Cowen raised their price target on Cencora from $350.00 to $400.00 and gave the stock a “buy” rating in a report on Monday, November 10th. Barclays started coverage on Cencora in a research note on Monday, December 8th. They set an “overweight” rating and a $400.00 price objective on the stock. UBS Group raised their target price on Cencora from $380.00 to $415.00 and gave the stock a “buy” rating in a research note on Friday, November 7th. Finally, Robert W. Baird set a $415.00 target price on Cencora in a report on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $381.42.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.